Patients who are experiencing ‘wearing-off’ may benefit from taking a catechol-O-methyltransferase inhibitor (COMT inhibitor).1,2 COMT inhibitors inhibit the breakdown of dopamine and of levodopa in the body, thus prolonging their therapeutic effect and time spent in ‘ON’ states.3
3-OMD=3-O-methyldopa; COMT=catechol-O-methyltransferase; COMTI=catechol-O-methyltransferase inhibitor; L-DOPA=levodopa; MAO-A=monoamine oxidase type A
Related content
Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease
Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure
Visual explanation of how MAO-B inhibitors help preserve dopamine levels in the synapse in Parkinson’s disease treatment